Surrey Heartlands

Joint Formulary & PAD

Prucalopride - Constipation

You are here : Home > Formulary Search > Prucalopride - Constipation

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NICE
Restrictions / Comments :
Important
Only after a trial of at least 2 other classes of laxative at the highest recommended, tolerated doses. Consider stopping after 4 weeks if not effective.

Documentation

NICE Technology Appraisal
NICE TA211 - Prucalopride for the treatment of chronic constipation in women

PAD Profile

ChemicalSubstance :
Prucalopride
Indication :
Constipation
Group Name :
Keywords :
NICE
Brand Names Include :
Resolor
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Constipation
Supporting Documents :
1

Other Indications

Below are listed other indications that Prucalopride is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Constipation.

Committee Recommendations (2)

03 Jul 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC have adopted the CKS principles for the management of constipation in adults.

Management | Constipation | CKS | NICE

The CKS guidance covers the management of constipation in adults (including pregnant women and those who are breastfeeding), for short-duration and chronic constipation, and faecal loading and/or impaction.

Refer to the formulary for Traffic Light status / place in therapy of locally agreed treatment options.

02 Oct 19 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Treatment with prucalopride (October 2019 review)

1. Patient should have been treated with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, and these treatments have failed to provide adequate relief and invasive treatment for constipation is being considered.

2. If treatment is not effective after 4 weeks then consider stopping treatment.